Key facts
- It has raised $32.5M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Feb 2025.
- Notable investors include F-Prime Capital, Canaan Partners, Eli Lilly, Yale University, Yosemite.
- Quarry Thera has filed 1 Form D with the SEC, most recently Feb 2025 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Quarry Thera
Funding rounds
1 roundsAbout Quarry Thera
Developer of proximity-driven therapeutics designed to overcome limitations in conventional drug modalities. The company integrates DNA-encoded libraries, guided drug design, and medicinal chemistry to target previously inaccessible protein interactions, enabling clients in the pharmaceutical market to explore therapies with improved selectivity, broader cellular permeability, and enhanced therapeutic indices across oncology and immunology applications.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2024
- Employees
- 8
- Ownership
- Privately Held (backing)
Quarry Thera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quarry Thera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quarry Thera in its N-PORT filings yet. We sweep new filings monthly.